Insulin glargine: pharmacokinetic and pharmacodynamic basis of clinical effect
Glargine became the first long-acting insulin analogue. Glargine was designed to meet basal insulin requirements throughout the day with a single injection. Pharmacokinetics of insulin glargine is characterized by biotransformation into metabolites M1 and M2 that transforms the B chain of glargine s...
Guardado en:
Autores principales: | Vadim Valer'evich Klimontov, Natalya Evgen'evna Myakina |
---|---|
Formato: | article |
Lenguaje: | EN RU |
Publicado: |
Endocrinology Research Centre
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/68134155cb3a4de7b6012ca1ba4f09a4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Enzyme-Linked Immunosorbent Assay Method Application in the Study of Comparative Pharmacokinetics of Insulin Glargin Preparations
por: L. N. Shitov, et al.
Publicado: (2019) -
Evaluation of biosimilarity of RinGlar® (GEROPHARM LLC, Russia) and Lantus® (Sanofi-Aventis Deutschland GmbH, Germany) using the euglycemic hyperinsulinemic clamp technique in patients with type 1 diabetes: double-blind randomized clinical trial
por: Alexander Y. Mayorov, et al.
Publicado: (2020) -
On the safety of insulin Glargine
por: Ivan Ivanovich Dedov, et al.
Publicado: (2009) -
Insulin glargine 300 U/mL for basal insulin therapy in type 1 and type 2 diabetes mellitus
por: Lau IT, et al.
Publicado: (2017) -
Metabolic and cardiovascular effects of early insulin glargin prescription: based on data from ORIGIN study
por: Elena Valer'evna Biryukova, et al.
Publicado: (2012)